APOSCREEN-1 - a prospective, single-arm clinical trial for the implementation of a pharmacy-based screening for cardiovascular-kidney-metabolic risk factors in Schleswig-Holstein - PubMed
3 hours ago
- #cardiovascular prevention
- #CKM syndrome
- #pharmacy screening
- APOSCREEN-1 is a prospective single-arm clinical trial evaluating pharmacy-based screening for cardiovascular-kidney-metabolic (CKM) risk factors.
- It aims to enhance early detection of CKM syndrome, a major driver of cardiovascular disease, by leveraging accessible community pharmacies.
- The study involves 1000 adults aged 40+ with risk criteria, using point-of-care tests for HbA1c, lipids, urinary albumin, and blood pressure.
- Primary outcomes include completion rates, pharmacy implementation metrics, and the number needed to screen to identify unknown or poorly managed risk factors.
- Secondary outcomes cover participant metrics, diagnostic accuracy, and clinical impact evaluation.
- Findings may support community pharmacies as additional access points for early CKM detection, addressing low participation in primary care screenings.
- The trial is registered in the German trial registry (DRKS00039149) and approved by the Ethics Committee of the Christian-Albrechts-University of Kiel.